CRISPR Therapeutics AG (CRSP) NASDAQ

73.97

+4.82(+6.97%)

Updated at October 20 04:00PM

Currency In USD

CRISPR Therapeutics AG

Address

Baarerstrasse 14

Zug, 6300

Switzerland

Phone

41 41 561 32 77

Sector

Healthcare

Industry

Biotechnology

Employees

393

First IPO Date

October 19, 2016

Key Executives

NameTitlePayYear Born
Dr. Samarth Kulkarni Ph.D.Chief Executive Officer & Chairman1.4M1978
Dr. Raju Yashaswi Prasad Ph.D.Chief Financial Officer755,9821984
Mr. James R. Kasinger J.D.General Counsel & Secretary756,9701972
Dr. Naimish Patel C.M., M.D.Chief Medical Officer917,3621972
Dr. Daniel G. Anderson Ph.D.Scientific Founder & Advisory Board Member0N/A
Dr. Matthew Porteus M.D., Ph.D.Scientific Founder & Advisory Board Member01965
Dr. Craig C. Mello Ph.D.Scientific Founder & Advisory Board Member0N/A
Mr. Shaun Foy CFAFounder0N/A
Dr. Emmanuelle Marie Charpentier Ph.D.Co-Founder & Scientific Advisory Board Member0N/A
Dr. Chad A. Cowan Ph.D.Scientific Founder01972

Description

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.